

NantKwest, Inc.  
Form SC 13G  
February 17, 2016

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO**

**RULE 13d-2(b)**

**(Amendment No.    )**

**NantKwest, Inc.**

**(Name of Issuer)**

**Common Stock, \$.0001 per share**

**(Title of Class of Securities)**

**63016Q102**

**(CUSIP Number)**

**December 31, 2015**

**(Date of Event Which Requires Filing of This Statement)**

Edgar Filing: NantKwest, Inc. - Form SC 13G

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

(Page 1 of 5 Pages)

13G

CUSIP No. 63016Q102

Page 2 of 5 Pages

1 NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

2 Sorrento Therapeutics, Inc.  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) " (b) "

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

USA  
5 SOLE VOTING POWER

NUMBER OF 5,618,326  
SHARES 6 SHARED VOTING POWER

BENEFICIALLY

OWNED BY 0  
7 SOLE DISPOSITIVE POWER  
EACH

REPORTING  
5,618,326  
PERSON WITH 8 SHARED DISPOSITIVE POWER

0  
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

10            5,618,326  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    "

11            PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12            6.92 \*  
TYPE OF REPORTING PERSON\*

CO

\* Based upon 81,220,377 shares of common stock outstanding as of October 31, 2015, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission (the SEC) on November 12, 2015.

Item 1(a). Name of Issuer:  
NantKwest, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:  
3530 John Hopkins Ct., San Diego, CA 92121.

Item 2(a). Name of Person Filing.

(b). Address of Principal Business Office or, if None, Residence.

(c). Citizenship.  
Sorrento Therapeutics, Inc.

9380 Judicial Drive

San Diego, CA 92121

USA

Item 2(d). Title of Class of Securities.  
Common Stock, \$.0001 par value

Item 2(e). CUSIP Number.  
63016Q102

Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b or (c), Check Whether the Person Filing is  
a:

- (a)  Broker or dealer registered under Section 15 of the Exchange Act.
- (b)  Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c)  Insurance Company as defined in Section 3(a)(19) of the Exchange Act.
- (d)  Investment Company registered under Section 8 of the Investment Company Act.
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

Edgar Filing: NantKwest, Inc. - Form SC 13G

- (f) " An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) " A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) " A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) " A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) " Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 5,618,326
- (b) Percent of class: 6.92%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 5,618,326
  - (ii) Shared power to vote or to direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 5,618,326
  - (iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below, the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 17, 2016

**SORRENTO THERAPEUTICS, INC.**

**By: /s/ Henry Ji, Ph.D.**

**Name: Henry Ji, Ph.D.**

**Title: CEO**